Polysaccharide-Targeting Lipid Nanoparticles to Kill Gram-Negative Bacteria

Medium-chain fatty acids and monoglycerides: Nanoarchitectonics-based insights into molecular self-assembly, membrane interactions, and applications

Medium-chain fatty acids (FAs) and monoglycerides (MGs) with saturated 6- to 12‑carbon long tails are single-chain lipid amphiphiles that demonstrate significant application merits. Key examples include their antimicrobial activity against antibiotic-resistant bacteria and emerging viral threats as well as innovations in oral pharmaceutics and biorenewable chemical production. These diverse functionalities are enabled by FA and MG self-assembly and their interactions with biological membranes. However, an integrated viewpoint connecting interfacial science principles to the broader application scope remains lacking. The objective of this review is to cover the latest progress in medium-chain FA and MG research and to build connections between molecular self-assembly, membrane interactions, and applications. By taking a bottom-up nanoarchitectonics perspective, we first examine molecular self-assembly principles, including ionization properties and formation of colloidal nanostructures such as micelles and vesicles. We then discuss membrane interaction concepts and experimental findings that illustrate how medium-chain FAs and MGs distinctly interact with phospholipid membranes. Based on this foundation, we highlight cutting-edge applications in medicine, agriculture, drug delivery, and sustainability, linking these advances to interfacial science concepts. In addition, we emphasize the growing convergence of experimental, theoretical, and computational approaches and offer a forward-looking perspective on future research needs and application opportunities.

Strategic use of nanomaterials as double-edged therapeutics to control carcinogenesis via regulation of dysbiosis and bacterial infection: current status and future prospects

The human microbiome plays a crucial role in modulating health and disease susceptibility through a complex network of interactions with the host. When the delicate balance of this microbial ecosystem is disrupted, it often correlates with the onset of systemic diseases. An over-abundance of pathogenic microorganisms within the microbiome has been implicated as a driving factor in the development of disease conditions such as diabetes, obesity, and chronic infections. It has been observed that microbiome dysbiosis perturbs metabolic, inflammatory, and immunological pathways, potentially facilitating carcinogenesis. Furthermore, the metabolites associated with microbial dysbiosis exert multifaceted effects, including metabolic interference, host DNA damage, and tumor promotion, further underscoring the microbiome's significance in several of the cancers. This new exploration of microbiome involvement in carcinogenesis needs additional patient sample analysis, which could provide new insights into cancer diagnosis and treatment. However, treating these diseases using drugs, traditional methods, etc. has resulted in multi-drug resistance, and this has eventually made the situation worrisome. This review highlights the importance of nanotechnology, which may tackle these pathogenic conditions simultaneously by targeting common receptors present in bacteria and cancer. Herein, we have explained how nanotechnology may come to the forefront for these treatments. It explores the potential of non-antibiotic disinfectants, i.e., nanoparticles (NPs) with dual targeting capabilities against microbes and cancer cells, using mechanisms such as ROS generation and DNA damage while minimizing the chances of drug resistance.

Neuraminidase and pH responsive nano-drug against resistant Glaesserella parasuis

Glaesserella parasuis (GPS) infection leads to significant economic losses in livestock, with antibiotic resistance exacerbating the issue. The lengthy development cycle of new drugs further complicates timely intervention. Neuraminidase, a virulence factor of GPS, plays a critical role in infection progression. This study presents PSA-Gly-TD, a dual-responsive nanomicelle drug delivery system designed to target neuraminidase and pH variations, offering a solution to the problem of drug-resistant GPS infections. By covalently linking polysialic acid with Tildipirosin, nanoparticles with excellent dispersibility, stability, and a drug encapsulation efficiency of 99.27 % were synthesized. The system demonstrated a particle size of 64.75 nm, accelerated drug release in pathological conditions, and significantly enhanced cellular uptake-nearly three times higher than Tildipirosin alone while maintaining cell viability above 90 %. PSA-Gly-TD preserved the antibacterial efficacy of Tildipirosin and exhibited superior bactericidal activity against drug-resistant GPS strains. In animal models, PSA-Gly-TD showed a stable metabolic profile, reduced tissue damage, and avoided hemolysis, making it a safe and effective option for treating drug-resistant bacterial infections. These results underscore PSA-Gly-TD as a promising therapeutic agent, offering an innovative approach to combating antimicrobial resistance in veterinary medicine and addressing critical challenges in livestock health.

An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections

Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.

Antibacterial carbon dots

Bacterial infections significantly threaten human health, leading to severe diseases and complications across multiple systems and organs. Antibiotics remain the primary treatment strategy for these infections. However, the growing resistance of bacteria to conventional antibiotics underscores the urgent need for safe and effective alternative treatments. In response, several approaches have been developed, including carbon dots (CDs), antimicrobial peptides, and antimicrobial polymers, all of which have proven effective in combating bacterial resistance. Among these, CDs stand out due to their unique advantages, including low preparation cost, stable physicochemical properties, high biocompatibility, tunable surface chemistry, strong photoluminescence, and efficient generation of reactive oxygen species. These features make CDs highly promising in antibacterial applications. This review explores the development of antibacterial CDs, focusing on their mechanisms of action-physical destroy, biochemical damage, and synergistic effects-while highlighting their potential for clinical use as antibacterial agents.

Recent advances in the extraction, purification, structural-property correlations, and antiobesity mechanism of traditional Chinese medicine-derived polysaccharides: a review

Traditional Chinese medicine (TCM) has displayed preventive and therapeutic effects on many complex diseases. As natural biological macromolecules, TCM-derived antiobesogenic polysaccharides (TCMPOs) exhibit notable weight-loss effects and are seen to be a viable tactic in the fight against obesity. Current studies demonstrate that the antiobesity activity of TCMPOs is closely related to their structural characteristics, which could be affected by the extraction and purification methods. Therefore, the extraction, purification and structural-property correlations of TCMPOs were discussed. Investigation of the antiobesity mechanism of TCMPOs is also essential for their improved application. Herein, the possible antiobesity mechanisms of TCMPOs are systematically summarized: (1) modulation of appetite and satiety effects, (2) suppression of fat absorption and synthesis, (3) alteration of the gut microbiota and their metabolites, and (4) protection of intestinal barriers. This collated information could provide some insights and offer a new therapeutic approach for the management and prevention of obesity.